Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

62.96
+0.56000.90%
Volume:807.35K
Turnover:50.78M
Market Cap:6.19B
PE:26.93
High:64.00
Open:62.45
Low:60.53
Close:62.40
Loading ...

TD Cowen Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
21 Jan

U.S. RESEARCH ROUNDUP- Apple, Murphy USA, UnitedHealth

Reuters
·
21 Jan

Sarepta Therapeutics Inc : Leerink Partners Cuts Target Price to $200 From $210

THOMSON REUTERS
·
20 Jan

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

Insider Monkey
·
20 Jan

Temporary Revenue Surge and Market Penetration Concerns Lead to Sell Rating for Sarepta Therapeutics

TIPRANKS
·
15 Jan

Sarepta Therapeutics Price Target Maintained With a $202.00/Share by Needham

Dow Jones
·
14 Jan

Sarepta Therapeutics (SRPT) Gets a Buy from Bank of America Securities

TIPRANKS
·
14 Jan

Sarepta’s Elevidys launch remains strong with solid beat, says JPMorgan

TIPRANKS
·
14 Jan

Sarepta Therapeutics: Strong Elevidys Launch and Promising Pipeline Drive Buy Rating

TIPRANKS
·
14 Jan

BRIEF-Sarepta Therapeutics Reiterates 2025 Rev Guidance Of $2.9 Bln-$3.1 Bln

Reuters
·
14 Jan

Sarepta Therapeutics Tops 2024 Net Product Revenue Guidance

Dow Jones
·
14 Jan

Sarepta Announces Q4 2024 Revenue Of $638.2M, Exceeding Guidance; ELEVIDYS Revenue At $384.2M; RNA PMO Revenue At $254M; FY24 Revenue Totals $1.79B; $1.5B In Cash And Investments At Year-End 2024; Reiterates 2025 Revenue Guidance Of $2.9B-$3.1B

Benzinga
·
14 Jan

Sarepta Therapeutics Q4 Revenue USD 638.2 Million VS. Ibes Estimate USD 585.1 Million

THOMSON REUTERS
·
14 Jan

Sarepta Therapeutics Inc - Reiterates 2025 Revenue Guidance of $2.9-$3.1 Bln

THOMSON REUTERS
·
14 Jan

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

THOMSON REUTERS
·
14 Jan

Stocks to Watch Monday: Nvidia, Tesla, MicroStrategy, Pfizer -- WSJ

Dow Jones
·
13 Jan

U.S. RESEARCH ROUNDUP-Accolade, Costco Wholesale, RH

Reuters
·
09 Jan

Sarepta Therapeutics Inc : Mizuho Cuts Target Price to $195 From $200

THOMSON REUTERS
·
09 Jan

Mizuho Securities Remains a Buy on Sarepta Therapeutics (SRPT)

TIPRANKS
·
09 Jan

RBC Cuts Price Target on Sarepta Therapeutics to $165 From $182, Keeps Outperform Rating

MT Newswires Live
·
07 Jan